Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

52.50USD
23 Oct 2014
Price Change (% chg)

$0.66 (+1.27%)
Prev Close
$51.84
Open
$52.01
Day's High
$52.89
Day's Low
$52.01
Volume
1,931,879
Avg. Vol
1,457,377
52-wk High
$57.49
52-wk Low
$46.32

BMY.N

Chart for BMY.N

About

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities... (more)

Overall

Beta: 0.39
Market Cap (Mil.): $87,039.99
Shares Outstanding (Mil.): 1,657.91
Dividend: 0.36
Yield (%): 2.74

Financials

  BMY.N Industry Sector
P/E (TTM): 32.55 32.88 33.65
EPS (TTM): 1.61 -- --
ROI: 10.07 18.21 17.48
ROE: 18.10 18.89 18.31
Search Stocks

ConvaTec owners appoint banks to explore sale: sources

LONDON - ConvaTec's owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said.

15 Oct 2014

ConvaTec owners appoint banks to explore sale - sources

LONDON, Oct 15 - ConvaTec's owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said.

15 Oct 2014

Bristol-Myers pulls U.S. marketing application for hep C treatment

NEW YORK - Bristol-Myers Squibb Co on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates.

07 Oct 2014

UPDATE 2-Bristol-Myers pulls U.S. marketing application for hep C treatment

(Adds comment from Bristol-Myers and analyst, adds background, updates shares)

07 Oct 2014

Bristol-Myers pulls U.S. marketing application for hepatitis C treatment

- Bristol-Myers Squibb said it withdrew its U.S. marketing application for an oral drug combination to treat hepatitis C, citing a "rapidly evolving" treatment landscape in the country.

07 Oct 2014

Bristol-Myers pulls U.S. marketing application for hepatitis C treatment

Oct 7 - Bristol-Myers Squibb said it withdrew its U.S. marketing application for a drug combination to treat hepatitis C.

07 Oct 2014

UPDATE 1-Novartis works with Bristol-Myers Squibb to test lung cancer drugs

ZURICH, Oct 6 - Swiss pharma group Novartis AG said on Monday it would work with Bristol-Myers Squibb Co to test the U.S. drugmaker's immuno-oncology drug Opdivo in combination with three of its own experimental lung cancer drugs.

06 Oct 2014

Novartis works with Bristol-Myers for lung cancer studies

ZURICH, Oct 6 - Swiss pharma group Novartis AG said on Monday it had entered into a clinical collaboration with Bristol-Myers Squibb Co to evaluate the safety and efficacy of combination treatments for patients with non-small cell lung cancer.

06 Oct 2014

Bristol immune drug shows strong effect in melanoma study

MADRID - Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option.

29 Sep 2014

UPDATE 1-Bristol immune drug shows strong effect in melanoma study

* 32 percent response rate in patients treated with Opdivo

29 Sep 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $102.63 +1.41
Pfizer Inc. (PFE.N) $28.60 +0.30
Merck & Co., Inc. (MRK.N) $56.63 +1.12
Sanofi SA (SASY.PA) €84.74 -0.16
AstraZeneca plc (AZN.L) 4,308.00p -26.50
GlaxoSmithKline plc (GSK.L) 1,418.50p +6.50
Eli Lilly and Co (LLY.N) $64.35 -0.33

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks